



Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from <https://aidsinfo.nih.gov/guidelines> on 8/31/2020

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <https://aidsinfo.nih.gov/e-news>.

When to Initiate Therapy in Antiretroviral-Naive Children (Last updated April 14, 2020; last reviewed April 14, 2020)

Panel's Recommendations

- Antiretroviral therapy (ART) should be initiated in all infants and children with HIV infection (AI for children aged <3 months, AI* for older children).
- Rapid ART initiation (defined as initiating ART immediately or within days of diagnosis), accompanied by a discussion of the importance of adherence and provision of subsequent adherence support, is recommended for all children with HIV.
- If a child with HIV has not initiated ART, health care providers should closely monitor the virologic, immunologic, and clinical status at least every 3 to 4 months (AIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

[†] Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents

Overview

The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends initiating treatment for all children with HIV. This recommendation is consistent with treatment recommendations for adults with HIV, as well as European recommendations for children with HIV issued by Pediatric European Network for Treatment of AIDS Treatment Guidelines.¹ Multiple studies have shown a benefit to early antiretroviral therapy (ART) initiation. In children aged <1 year, the health and survival benefit of immediate ART initiation has been clearly demonstrated in the CHER trial.² In addition, in a study of two cohorts of infants with HIV in Johannesburg, South Africa, infants who initiated ART at ages <6 months had better sustained viral control after achieving suppression than infants who started therapy between the ages of 6 and 24 months.³ Several studies have reported that treatment initiation within the first year of life is also associated with reduced size of viral reservoirs.⁴⁻⁹ An observational study of more than 20,000 children aged 1 year to 16 years from 19 cohorts in Europe, Southern Africa, and West Africa found that immediate ART was associated with lower mortality and better growth in children aged <10 years when compared with ART that was delayed until CD4 T lymphocyte (CD4) cell count decreased to <350 cells/mm³.¹⁰ Ongoing viral replication may be associated with persistent inflammation and the development of cardiovascular, kidney, and liver disease and malignancy; studies in adults also suggest that early control of replication may reduce the risk of these non-AIDS complications.¹¹⁻¹⁵

In addition to the health benefits of rapid treatment initiation, which is defined as therapy that is initiated immediately or within days of diagnosis, treatment initiation in young infants with HIV during the early stages of HIV infection may control viral replication before HIV can evolve into diverse and potentially more pathogenic quasi-species.¹⁶ Initiation of therapy at higher CD4 counts has been associated with the presence of fewer drug-resistance mutations at virologic failure in adults.¹⁷ Early therapy also preserves immune function, preventing clinical disease progression.¹⁸⁻²⁰

Survival and Health Benefits Associated with Early Treatment Initiation

The CHER trial was a randomized clinical trial in South Africa that initiated triple-drug ART in asymptomatic infants aged 6 to 12 weeks with perinatally acquired HIV and normal CD4 percentages (>25%). Immediate initiation of ART resulted in a 75% reduction in early mortality among these infants, compared with delaying treatment until the infants met clinical or immune criteria.² Most of the infant deaths in the delayed treatment arm occurred during the first 6 months after study entry. Consistent with the CHER trial, data from a number of observational studies in the United States, Europe, and South Africa

demonstrated that infants who receive early treatment are less likely to progress to AIDS or death, and they also have improved growth compared to those who start therapy later.²¹⁻²³

Older children with Centers for Disease Control and Prevention (CDC) Clinical Stage 3-defining opportunistic infections (OIs) (see [Revised Surveillance Case Definition for HIV Infection](#) and Table 6) are at high risk of disease progression and death. In general, studies that evaluate later initiation of ART in children have a selection bias, because children with perinatal infection and rapidly progressing disease may have died prior to receiving an HIV diagnosis or ART; children who present later for ART initiation may be slower progressors with a better prognosis. However, a general trend toward lower mortality and better growth with earlier ART initiation was reported in an evaluation of observational data from 20,756 ART-naïve children aged 1 year to 16 years at enrollment from 19 cohorts in Europe, Southern Africa, and West Africa.¹⁰ In children aged <10 years at enrollment, there was lower mortality and higher mean height-for-age z-score after 5 years of follow-up among participants who initiated ART immediately than among those who delayed treatment until their CD4 counts decreased to <350 cells/mm³. The multicenter, open-label PREDICT trial randomized 300 children with HIV aged 1 year to 12 years at enrollment (median age 6.4 years) to immediately initiate ART or to defer treatment until their CD4 percentage was <15%; the study reported better height gain among children who started ART immediately.²⁴ Similarly, other studies have reported an association between younger age at initiation of therapy and more rapid growth reconstitution.^{22,25-27} U.S. and international studies have reported an association between delayed ART initiation and delay of pubertal development and menarche.²⁸⁻³⁰ In a study of Zimbabwean children (median age 11 years), earlier ART initiation and improved nutrition were positively associated with improved lung function.³¹

Neurodevelopmental Benefits Associated with Early Treatment Initiation

A CHER trial substudy found that infants who initiated treatment early had significantly better gross motor and neurodevelopmental profiles than those whose therapy was deferred.³² In a study of Kenyan infants with HIV who initiated treatment before 6 months of age and who were on treatment for at least 6 months, infants with an effective response to treatment had better gross motor and language attainment than infants who did not meet the parameters for effective treatment response.³³ In this study, an effective response to treatment was defined as HIV RNA <1,000 copies/mL, CD4 percentages ≥25%, and weight-for-age z-scores ≥-2 at 9 months of age. A study of South African infants with perinatal HIV infection who initiated treatment within 21 days of life (median 6 days) found that early neurodevelopmental scores for these infants were within the normal range.³⁴

Immune Benefits Associated with Early Treatment Initiation

In the CHER study, infants who were treated early had decreased immune activation, greater recovery of CD4 cells, expanded CD4 naïve T cells, and retention of innate effector frequencies, resulting in greater immune reconstitution than that achieved in infants who received deferred ART.²⁰ In a small study in Botswana, infants who initiated ART within the first 7 days of life were found to have decreased immune activation, a more poly-functional HIV-1-specific CD8 cell response, and a markedly reduced HIV latent reservoir compared with infants who initiated ART later in the first year of life.⁹ Shiao et al. reported that, among two cohorts of South African infants with HIV, those who initiated ART at ages <6 months had better sustained viral control after achieving suppression than infants who started therapy between 6 and 24 months.³ Available data suggest that both children and adults who initiate treatment with a higher CD4 percentage or CD4 count have better immune recovery than patients who initiate with lower CD4 percentages or CD4 counts.^{26,35-37} Among 1,236 children with perinatally acquired HIV in the United States, only 36% of those who started treatment with CD4 percentages <15% achieved CD4 percentages >25% after 5 years of therapy, compared with 59% of children who started with CD4 percentages of 15% to 24%.³⁸ Finally, earlier age at ART initiation results in higher rates of CD4:CD8 ratio normalization and improved immunogenicity of childhood vaccines.³⁹⁻⁴¹

Early initiation of suppressive ART (i.e., in infants aged <6 months) results in a significant proportion of infants with HIV who fail to produce their own HIV-specific antibodies. These infants appear to be HIV

seronegative when tested; however, viral reservoirs remain, and viral rebound occurs if ART is stopped.⁴²⁻⁴⁶

Viral Reservoirs and Viral Suppression with Early Treatment Initiation

Several studies have reported that early treatment of infants with perinatally acquired HIV is also associated with reduced size of viral reservoirs.^{4-7,9,47} Many studies that compared the size of viral reservoirs in children who initiated ART before age 12 weeks to those who initiated ART at ≥ 12 weeks to ≤ 2 years of age have found that viral reservoir size (as measured by peripheral blood mononuclear cell [PBMC] HIV DNA levels) after 1 year and 4 years of ART significantly correlated with the age at ART initiation and the age at viral control.⁴⁸⁻⁵⁰ Kuhn et al. found that initiating ART at a younger age was associated with lower levels of PBMC-associated HIV DNA. Furthermore, the authors reported that risk of viral rebound to >50 copies/mL was two-fold higher ($P = 0.0006$) in the first 36 months after treatment initiation for infants with HIV DNA reservoir levels >55 copies/ 10^6 cells than for infants with HIV DNA reservoir levels ≤ 55 copies/ 10^6 cells.⁴ Similarly, in a cross-sectional substudy of 144 youth with perinatally acquired HIV and long-term viral suppression in the Pediatric HIV/AIDS Cohort Study (PHACS)/Adolescent Master Protocol (AMP) study, a lower proviral reservoir was found in those who achieved virologic control at <1 year of age than in those who achieved virologic control at 1 to 5 years of age or >5 years of age (4.2 vs. 19.4 vs. 70.7 copies/million PBMCs, respectively).⁵¹ In addition, among 61 children with perinatally acquired HIV in PHACS who achieved viral suppression at ages of <1 year versus ages between 1 and 5 years, the mean half-life of HIV DNA from the time of viral suppression was shorter in the early suppressors—5.9 years versus 18.8 years, respectively.⁵²

These findings may indicate that initiating treatment soon after an infant acquires HIV can limit the size of the HIV viral reservoir, and that smaller reservoirs provide some level of protection against viral rebound in the setting of treatment nonadherence, a likely event for infants with HIV, who are destined for life-long treatment. Furthermore, near-complete control of viral replication has been reported in infants who initiated treatment early and who had sustained control of plasma viremia.^{42,53}

The report of a prolonged remission in a child with perinatally acquired HIV in Mississippi generated discussion about early initiation of ART as presumptive treatment in newborns at high risk of HIV acquisition. This newborn, born to a mother who did not receive antenatal or perinatal ART, was treated with a three-drug antiretroviral (ARV) regimen at age 30 hours **that was continued following diagnostic testing that confirmed HIV infection. ART was continued** through age 18 months, and then discontinued against medical advice. Intensive follow-up evaluations showed no evidence of virologic rebound following discontinuation of ART until age 46 months (27 months after the discontinuation of ART), when the plasma viral load rebounded to 16,750 copies/mL; this viral load was confirmed with repeat testing. ART was restarted at that time.^{54,55}

This experience has prompted increasing support for initiating treatment as soon as the diagnosis is made during the first weeks of life, **to limit reservoir formation and possibly facilitate ART-free remission**. Although there are a limited number of case reports of lengthy remissions in children with perinatally acquired HIV **who have undergone treatment interruption**, current ARV regimens have not been shown to eradicate HIV infection because HIV persists in CD4 cells and other long-lived cells.⁵⁶⁻⁵⁹ For these reasons, the Panel **does not recommend** empiric treatment interruption.

Managing treatment in neonates with HIV is complex from both a medical and social perspective. Because of limited safety and pharmacokinetic (PK) data for ARV drugs in full-term infants aged <2 weeks and preterm infants aged ≤ 4 weeks, drug and dose selection in this age group is challenging (see [What to Start](#) and [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#)).^{60,61} Hepatic and renal function are immature in newborns, who are undergoing rapid maturational changes during the first few months of life. This can result in substantial differences in ARV dose requirements between young infants and older children.⁶² When drug concentrations are subtherapeutic, either because of inadequate dosing, poor absorption, or incomplete adherence, ARV drug resistance can develop rapidly, particularly in young infants, who experience high levels of viral replication. Frequent follow-up for dose optimization during periods of rapid growth is especially important when treating young infants. Furthermore, clinicians should continually assess a patient's adherence and address potential barriers to adherence during this time (see [Adherence to](#)

Summary

Multiple studies have reported that early treatment initiation is associated with immune, growth, and neurodevelopmental benefits. In addition, early treatment initiation may limit the formation of the viral reservoir. The Panel recommends rapid initiation of ART (defined as initiating ART immediately or within days of diagnosis) for all children who receive an HIV diagnosis. The urgency of rapid treatment initiation is especially critical for children aged <1 year, who carry the highest risk of rapid disease progression and mortality. However, it is worth noting that treatment of full-term infants aged ≤2 weeks and preterm infants is complex, due to the limited data on the PKs and appropriate dosing of ARV drugs in this age group; this is an area of active investigation (see [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#)).⁶¹ An exception to rapid initiation is that ART should be deferred in patients with tuberculosis or cryptococcal meningitis until treatment for these OIs has been tolerated for at least 2 weeks; appropriate timing of ART initiation in these cases should be discussed with a pediatric HIV specialist.

While therapy is being initiated, it is important to assess and discuss issues associated with adherence with caregivers and, when developmentally appropriate, with children. Intensive follow-up during the first few weeks to months after treatment initiation is also recommended to support the child and caregiver. Medication adherence is the core requirement for successful virologic control. The Panel recognizes that achieving consistent adherence in children is often challenging.^{63,64} Incomplete adherence leads to loss of viral control and the selection of drug resistance mutations, but forcibly administering ARV drugs to younger children may result in treatment aversion. The need for life-long therapy can also lead to treatment fatigue, which occurs among many children with perinatally acquired HIV during adolescence.⁶⁵

The Panel believes the benefits of early ART initiation outweigh the potential risks and recommends rapid initiation of ART in all children regardless of clinical, immunologic, or virologic status. However, individual clinical and/or psychosocial factors may lead patients, caregivers, and providers to make a collaborative decision to defer therapy. When making the decision to defer therapy, medical factors (e.g., the opportunity to limit seeding of the viral reservoir in newborns, the child's HIV disease stage [see Table 5], the presence of HIV-related signs and symptoms [see Table 6]) need to be balanced against any potential barriers to rapid treatment initiation. If therapy is deferred, the health care provider should closely monitor a child's virologic, immunologic, and clinical status at least every 3 to 4 months (AIII) (see [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)). Clinicians should initiate ART in children with HIV in whom treatment has been deferred when:

- HIV RNA levels increase,
- CD4 count or percentage values decline (e.g., approaching CDC Stage 2 or 3; see Table 5),
- The child develops new HIV-related clinical symptoms (see Table 6), or
- The ability of a caregiver and child to adhere to the prescribed regimen improves.

Table 5. HIV Infection Stage Based on Age-Specific CD4 Count or Percentage

Stage ^a	Aged <1 Year		Aged 1 Year to <6 Years		Aged ≥6 Years	
	Cells/mm ³	%	Cells/mm ³	%	Cells/mm ³	%
1	≥1,500	≥34	≥1,000	≥30	≥500	≥26
2	750–1,499	26–33	500–999	22–29	200–499	14–25
3	<750	<26	<500	<22	<200	<14

^a The stage is based primarily on the CD4 count; the CD4 count takes precedence over the CD4 percentage, and the percentage is considered only when the count is missing. If a Stage 3-defining condition has been diagnosed (see Table 6), then the stage is 3 regardless of CD4 test results.

Source: Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection—United States, 2014. *MMWR* 2014;63(No. RR-3):1-10.

Key: CD4 = CD4 T lymphocyte

Table 6. HIV-Related Symptoms and Conditions (page 1 of 2)

Mildly Symptomatic
<p>Children with two or more of the following conditions, but none of the conditions listed in the Moderately Symptomatic category, are considered mildly symptomatic:</p> <ul style="list-style-type: none"> • Lymphadenopathy (lymph nodes are ≥ 0.5 cm at more than two sites and/or bilateral at one site) • Hepatomegaly • Splenomegaly • Dermatitis • Parotitis • Recurrent or persistent upper respiratory tract infection, sinusitis, or otitis media
Moderately Symptomatic
<ul style="list-style-type: none"> • Anemia (hemoglobin < 8 g/dL [< 80 g/L]), neutropenia (white blood cell count $< 1,000$ per μL [$< 1.0 \times 10^9$ per L]), and/or thrombocytopenia (platelet count $< 100 \times 10^3$ per μL [$< 100 \times 10^9$ per L]) persisting for ≥ 30 days • Bacterial meningitis, pneumonia, or sepsis (single episode) • Candidiasis, oropharyngeal (thrush), persisting for > 2 months in children aged > 6 months • Cardiomyopathy • CMV infection, with onset before age 1 month • Diarrhea, recurrent or chronic • Hepatitis • HSV stomatitis, recurrent (more than two episodes within 1 year) • HSV bronchitis, pneumonitis, or esophagitis with onset before age 1 month • Herpes zoster (shingles) involving at least two distinct episodes or more than one dermatome • Leiomyosarcoma • Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex • Nephropathy • Nocardiosis • Persistent fever (lasting > 1 month) • Toxoplasmosis, onset before age 1 month • Varicella, disseminated (complicated chickenpox)
AIDS-Defining Conditions
<ul style="list-style-type: none"> • Bacterial infections, multiple or recurrent^a • Candidiasis of bronchi, trachea, or lungs • Candidiasis of esophagus • Cervical cancer, invasive • Coccidioidomycosis, disseminated or extrapulmonary • Cryptococcosis, extrapulmonary • Cryptosporidiosis, chronic intestinal (> 1 month duration) • CMV disease (other than liver, spleen, or lymph nodes), onset at age > 1 month • CMV retinitis (with loss of vision) • Encephalopathy attributed to HIV^b • HSV: chronic ulcers (> 1 month duration) or bronchitis, pneumonitis, or esophagitis (onset at age > 1 month) • Histoplasmosis, disseminated or extrapulmonary • Isosporiasis, chronic intestinal (> 1 month duration) • Kaposi sarcoma • Lymphoma, Burkitt (or equivalent term) • Lymphoma, immunoblastic (or equivalent term) • Lymphoma, primary, of brain • <i>Mycobacterium avium</i> complex or <i>Mycobacterium kansasii</i>, disseminated or extrapulmonary

Table 6. HIV-Related Symptoms and Conditions (page 2 of 2)

AIDS-Defining Conditions, continued
<ul style="list-style-type: none"> • <i>Mycobacterium tuberculosis</i> of any site, pulmonary, disseminated, or extrapulmonary • <i>Mycobacterium</i>, other species or unidentified species, disseminated or extrapulmonary • <i>Pneumocystis jirovecii</i> (previously known as <i>Pneumocystis carinii</i>) pneumonia • Pneumonia, recurrent^c • Progressive multifocal leukoencephalopathy • Salmonella septicemia, recurrent • Toxoplasmosis of brain, onset at age >1 month • Wasting syndrome attributed to HIV^b

^a Only among children aged <6 years.

^b Suggested diagnostic criteria for these illnesses, which might be particularly important for HIV encephalopathy and HIV wasting syndrome, are described in the following references:

Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR*. 1994;43(No. RR-12).

Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR*. 1992;41(No. RR-17).

^c Only among adults, adolescents, and children aged ≥6 years.

Key: CMV = cytomegalovirus; HSV = herpes simplex virus

Modified from:

Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR*. 1994;43(No. RR-12).

Centers for Disease Control and Prevention: Revised Surveillance Case Definition for HIV Infection—United States, 2014. *MMWR*. 2014;63(No. RR-3):1-10.

References

1. Foster C, Bamford A, Turkova A, et al. Paediatric European network for treatment of AIDS treatment guideline 2016 update: antiretroviral therapy recommended for all children living with HIV. *HIV Med*. 2017;18(2):133-134. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27385585>.
2. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. *N Engl J Med*. 2008;359(21):2233-2244. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19020325>.
3. Shiao S, Strehlau R, Technau KG, et al. Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants. *AIDS*. 2017;31(3):355-364. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27828785>.
4. Kuhn L, Paximadis M, Da Costa Dias B, et al. Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children. *PLoS One*. 2018;13(4):e0195514. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29649264>.
5. Massanella M, Ananworanich J, Leyre L, et al. ARV prophylaxis/ART initiation at birth limits the size of the reservoir in children. Abstract 135. Presented at: Conference on Retroviruses and Opportunistic Infections. 2018. Boston, Massachusetts. Available at: <http://www.croiconference.org/sessions/arv-prophylaxisart-initiation-birth-limits-size-reservoir-children>.
6. Shapiro RL, Lichterfeld M, Hughes MD, et al. Low HIV reservoir at 84 weeks in very early treated HIV-infected children in Botswana. Abstract 136. Presented at: Conference on Retroviruses and Opportunistic Infections. 2018. Boston, Massachusetts. Available at: <http://www.croiconference.org/sessions/low-hiv-reservoir-84-weeks-very-early-treated-hiv-infected-children-botswana>.
7. Tagarro A, Chan M, Zangari P, et al. Early and highly suppressive antiretroviral therapy are main factors associated with

low viral reservoir in European perinatally HIV-infected children. *J Acquir Immune Defic Syndr*. 2018;79(2):269-276. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30211778>.

8. Veldsman KA, Janse van Rensburg A, Isaacs S, et al. HIV-1 DNA decay is faster in children who initiate ART shortly after birth than later. *J Int AIDS Soc*. 2019;22(8):e25368. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31441231>.
9. Garcia-Broncano P, Maddali S, Einkauf KB, et al. Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. *Sci Transl Med*. 2019;11(520). Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31776292>.
10. Schomaker M, Leroy V, Wolfs T, et al. Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. *Int J Epidemiol*. 2017;46(2):453-465. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27342220>.
11. Longenecker CT, Triant VA. Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? *Curr Opin HIV AIDS*. 2014;9(1):54-62. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24275676>.
12. Ghislain M, Bastard JP, Meyer L, et al. Late antiretroviral therapy (ART) initiation is associated with long-term persistence of systemic inflammation and metabolic abnormalities. *PLoS One*. 2015;10(12):e0144317. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26636578>.
13. Achhra AC, Mocroft A, Ross M, et al. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. *Int J Antimicrob Agents*. 2017;50(3):453-460. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28668686>.
14. Lundgren JD, Borges AH, Neaton JD. Serious non-AIDS conditions in HIV: benefit of early ART. *Curr HIV/AIDS Rep*. 2018;15(2):162-171. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29504063>.
15. Dharan NJ, Neuhaus J, Rockstroh JK, et al. Benefit of early versus deferred antiretroviral therapy on progression of liver fibrosis among people with HIV in the START randomized trial. *Hepatology*. 2019;69(3):1135-1150. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30298608>.
16. Persaud D, Ray SC, Kajdas J, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. *AIDS Res Hum Retroviruses*. 2007;23(3):381-390. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17411371>.
17. Palumbo PJ, Fogel JM, Hudelson SE, et al. HIV drug resistance in adults receiving early vs. delayed antiretroviral therapy: HPTN 052. *J Acquir Immune Defic Syndr*. 2018;77(5):484-491. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29293156>.
18. Rinaldi S, Pallikkuth S, Cameron M, et al. Impact of early antiretroviral therapy initiation on HIV-specific CD4 and CD8 T cell function in perinatally infected children. *J Immunol*. 2020;204(3):540-549. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31889024>.
19. Planchais C, Hocqueloux L, Ibanez C, et al. Early antiretroviral therapy preserves functional follicular helper T and HIV-specific B cells in the gut mucosa of HIV-1-infected individuals. *J Immunol*. 2018;200(10):3519-3529. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29632141>.
20. Azzoni L, Barbour R, Papasavvas E, et al. Early ART results in greater immune reconstitution benefits in HIV-infected infants: working with data missingness in a longitudinal dataset. *PLoS One*. 2015;10(12):e0145320. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26671450>.
21. Goetghebuer T, Le Chenadec J, Haelterman E, et al. Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. *Clin Infect Dis*. 2012;54(6):878-881. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22198788>.
22. Shiao S, Arpadi S, Strehlau R, et al. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. *J Pediatr*. 2013;162(6):1138-1145 e1132. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23312691>.

23. Iyun V, Technau KG, Eley B, et al. Earlier antiretroviral therapy initiation and decreasing mortality among HIV-infected infants initiating antiretroviral therapy within 3 months of age in South Africa, 2006-2017. *Pediatr Infect Dis J*. 2020;39(2):127-133. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31725119>.
24. Puthanakit T, Saphonn V, Ananworanich J, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. *Lancet Infect Dis*. 2012;12(12):933-941. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23059199>.
25. McGrath CJ, Chung MH, Richardson BA, Benki-Nugent S, Warui D, John-Stewart GC. Younger age at HAART initiation is associated with more rapid growth reconstitution. *AIDS*. 2011;25(3):345-355. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21102302>.
26. Simms V, Rylance S, Bandason T, et al. CD4+ cell count recovery following initiation of HIV antiretroviral therapy in older childhood and adolescence. *AIDS*. 2018;32(14):1977-1982. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29927784>.
27. Traisathit P, Urien S, Le Coeur S, et al. Impact of antiretroviral treatment on height evolution of HIV infected children. *BMC Pediatr*. 2019;19(1):287. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31421667>.
28. Szubert AJ, Musiime V, Bwakura-Dangarembizi M, et al. Pubertal development in HIV-infected African children on first-line antiretroviral therapy. *AIDS*. 2015;29(5):609-618. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25710288>.
29. Williams PL, Jesson J. Growth and pubertal development in HIV-infected adolescents. *Curr Opin HIV AIDS*. 2018;13(3):179-186. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29432228>.
30. Williams PL, Abzug MJ, Jacobson DL, et al. Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. *AIDS*. 2013;27(12):1959-1970. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24145244>.
31. Rylance S, Rylance J, McHugh G, et al. Effect of antiretroviral therapy on longitudinal lung function trends in older children and adolescents with HIV-infection. *PLoS One*. 2019;14(3):e0213556. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30897116>.
32. Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. *AIDS*. 2012;26(13):1685-1690. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22614886>.
33. Benki-Nugent S, Wamalwa D, Langat A, et al. Comparison of developmental milestone attainment in early treated HIV-infected infants versus HIV-unexposed infants: a prospective cohort study. *BMC Pediatr*. 2017;17(1):24. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28095807>.
34. Laughton B, Naidoo S, Dobbels E, et al. Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life. *South Afr J HIV Med*. 2019;20(1):1008. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31745434>.
35. Picat MQ, Lewis J, Musiime V, et al. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. *PLoS Med*. 2013;10(10):e1001542. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24204216>.
36. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. *N Engl J Med*. 2013;368(3):218-230. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23323898>.
37. Desmonde S, Dicko F, Koueta F, et al. Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected children. *AIDS*. 2014;28(11):1645-1655. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24804858>.
38. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. *Clin Infect Dis*. 2008;46(4):507-515. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18199042>.
39. Seers T, Vassallo P, Pollock K, Thornhill JP, Fidler S, Foster C. CD4:CD8 ratio in children with perinatally acquired HIV-1 infection. *HIV Med*. 2018;19(9):668-672. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30084150>.

40. Moonsamy S, Suchard M, Madhi SA. Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants. *PLoS One*. 2019;14(4):e0215079. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31002702>.
41. Pensiero S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. *Proc Natl Acad Sci USA*. 2009;106(19):7939-7944. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19416836>.
42. Ananworanich J, Puthanakit T, Suntarattiwong P, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. *AIDS*. 2014;28(7):1015-1020. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24384692>.
43. Payne H, Mkhize N, Otjombe K, et al. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the children with HIV early antiretroviral therapy (CHER) trial: a retrospective analysis. *Lancet Infect Dis*. 2015;15(7):803-809. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26043884>.
44. Kuhn L, Schramm DB, Shiao S, et al. Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. *AIDS*. 2015;29(9):1053-1060. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25870988>.
45. Butler KM, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. *Pediatr Infect Dis J*. 2015;34(3):e48-51. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25742088>.
46. Wamalwa D, Benki-Nugent S, Langat A, et al. Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy. *AIDS*. 2016;30(15):2303-2313. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27177316>.
47. Foster C, Pace M, Kaye S, et al. Early antiretroviral therapy reduces HIV DNA following perinatal HIV infection. *AIDS*. 2017;31(13):1847-1851. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28609403>.
48. McManus M, Mick E, Hudson R, et al. Early combination antiretroviral therapy limits exposure to HIV-1 replication and cell-associated HIV-1 DNA levels in infants. *PLoS One*. 2016;11(4):e0154391. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27104621>.
49. Martinez-Bonet M, Puertas MC, Fortuny C, et al. Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy. *Clin Infect Dis*. 2015;61(7):1169-1178. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26063721>.
50. van Zyl GU, Bedison MA, van Rensburg AJ, Laughton B, Cotton MF, Mellors JW. Early antiretroviral therapy in South African children reduces HIV-1-infected cells and cell-associated HIV-1 RNA in blood mononuclear cells. *J Infect Dis*. 2015;212(1):39-43. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25538273>.
51. Persaud D, Patel K, Karalius B, et al. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. *JAMA Pediatr*. 2014;168(12):1138-1146. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25286283>.
52. Uprety P, Patel K, Karalius B, et al. Human immunodeficiency virus type 1 DNA decay dynamics with early, long-term virologic control of perinatal infection. *Clin Infect Dis*. 2017;64(11):1471-1478. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28329153>.
53. Bitnun A, Samson L, Chun TW, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. *Clin Infect Dis*. 2014;59(7):1012-1019. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24917662>.
54. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. *N Engl J Med*. 2013;369(19):1828-1835. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24152233>.
55. Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. *N Engl J Med*. 2015;372(8):786-788. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25693029>.

56. Frange P, Faye A, Avettand-Fenoel V, et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. *Lancet HIV*. 2016;3(1):e49-54. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26762993>.
57. Violari A, Cotton MF, Kuhn L, et al. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. *Nat Commun*. 2019;10(1):412. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30679439>.
58. Shiao S, Abrams EJ, Arpadi SM, Kuhn L. Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission? *Lancet HIV*. 2018;5(5):e250-e258. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29739699>.
59. Koofhethile CK, Moyo S, Kotokwe KP, et al. Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination: a case report with implications for clinical care. *Medicine (Baltimore)*. 2019;98(47):e18014. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31764816>.
60. Cotton MF, Holgate S, Nelson A, Rabie H, Wedderburn C, Mirochnick M. The last and first frontier—emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. *J Int AIDS Soc*. 2015;18(Suppl 6):20271. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26639118>.
61. Clarke DF, Penazzato M, Capparelli E, et al. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. *Expert Rev Clin Pharmacol*. 2018;11(1):83-93. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29039686>.
62. Chadwick EG, Yogev R, Alvero CG, et al. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. *AIDS*. 2011;25(5):643-649. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21297419>.
63. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. *Annu Rev Med*. 2010;61:169-185. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19622036>.
64. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. *Pediatrics*. 2007;119(6):e1371-1383. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17533177>.
65. Kacanek D, Huo Y, Malee K, et al. Nonadherence and unsuppressed viral load across adolescence among U.S. youth with perinatally acquired HIV. *AIDS*. 2019. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31274538>.